|
Characteristic
|
Crude HR (95% CI)
|
P-value* (bivariatea)
|
Adjusted HR (95% CI)
|
P-value* (multivariablea)
|
|---|
|
Primary tumor location
|
|
Right vs. Left
|
2.09 (1.31–3.33)
|
0.002
|
1.55 (0.92–2.61)
|
0.099
|
|
Age
|
|
>60 years vs. ≤ 60
|
0.77 (0.54–1.08)
|
0.133
|
0.77 (0.53–1.13)
|
0.180
|
|
Gender
|
|
Female vs. Male
|
1.15 (0.80–1.64)
|
0.449
|
1.11 (0.75–1.64)
|
0.616
|
|
Stage at presentation
|
|
Stage IV vs. Stage I-III
|
0.99 (0.66–1.49)
|
0.965
| | |
|
Histologic grade
|
|
P/D or SRC vs. W/D or M/D
|
5.37(2.24–12.87)
|
<0.001
|
3.06 (1.22–7.67)
|
0.017
|
|
Presence of liver metastasis
|
|
Yes vs. No
|
1.04 (0.73–1.50)
|
0.816
| | |
|
Presence of lung metastasis
|
|
Yes vs. No
|
0.87 (0.63–1.21)
|
0.419
| | |
|
Presence of peritoneal metastasis
|
|
Yes vs. No
|
2.53 (1.53–4.19)
|
<0.001
|
2.08 (1.19–3.63)
|
0.010
|
|
Number of metastasized organs
|
|
≥ 2 vs. 1
|
1.11 (0.80–1.53)
|
0.543
| | |
|
BRAF
|
|
Mutant vs. Wild-type
|
3.56 (2.11–6.01)
|
<0.001
|
3.07 (1.73–5.46)
|
<0.001
|
|
PIK3CA
|
|
Mutant vs. Wild-type
|
2.60 (0.95–7.11)
|
0.062
| | |
- Abbreviations: HR hazard ratio, CI confidence interval, P/D poorly differentiated, SRCC signet ring cell carcinoma, W/D well-differentiated, M/D moderately differentiated
-
*P-value by Cox’s proportional hazards regression
-
aClinically meaningful variables and those with p < 0.05 by bivariate analysis were entered into the multivariable analysis model
